Document Detail


Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo.
MedLine Citation:
PMID:  23379366     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many life-threatening diseases are disseminated through biological fluids, such as blood, lymph, and cerebrospinal fluid. The migration of tumor cells through the vascular circulation is a mandatory step in metastasis, which is responsible for ∼90% of cancer-associated mortality. Circulating pathogenic bacteria, viruses, or blood clots lead to other serious conditions including bacteremia, sepsis, viremia, infarction, and stroke. Therefore, technologies capable of detecting circulating tumor cells (CTCs), circulating bacterial cells (CBCs), circulating endothelial cells (CECs), circulating blood clots, cancer biomarkers such as microparticles and exosomes, which contain important microRNA signatures, and other abnormal features such as malaria parasites in biological fluids may facilitate early diagnosis and treatment of metastatic cancers, infections, and adverse cardiovascular events. Unfortunately, even in a disease setting, circulating abnormal cells are rare events that are easily obscured by the overwhelming background material in whole blood. Existing detection methods mostly rely on ex vivo analyses of limited volumes (a few milliliters) of blood samples. These small volumes limit the probability of detecting CTCs, CECs, CBCs and other rare phenomena. In vivo detection platforms capable of continuously monitoring the entire blood volume may substantially increase the probability of detecting circulating abnormal cells and, in particular, increase the opportunity to identify exceedingly rare and potentially dangerous subsets of these cells, such as circulating cancer stem cells (CCSCs). In addition, in vivo detection technologies capable of destroying and/or capturing circulating abnormal cells may inhibit disease progression. This review focuses on novel therapeutic and diagnostic (theranostic) platforms integrating in vivo real-time early diagnosis and nano-bubble based targeted therapy of CTCs, CECs, CBCs and other abnormal objects in circulation. This critical review particularly focuses on nanotechnology-based theranostic (nanotheranostic) approaches, especially in vivo photoacoustic (PA) and photothermal (PT) nanotheranostic platforms. We emphasize an urgent need for in vivo platforms composed of multifunctional contrast nanoagents, which utilize diverse modalities to realize a breakthrough for early detection and treatment of harmful diseases disseminated through the circulation.
Authors:
Jin-Woo Kim; Ekaterina I Galanzha; David A Zaharoff; Robert J Griffin; Vladimir P Zharov
Related Documents :
24886976 - Type 1 regulatory t cells specific for collagen-type ii as an efficient cell-based ther...
23733536 - Whole body mri and fluorescent microscopy for detection of stem cells labeled with supe...
23474756 - Aberrant mer receptor tyrosine kinase expression contributes to leukemogenesis in acute...
24556396 - Maits, mr1 and vitamin b metabolites.
23785406 - Th cells promote ctl survival and memory via acquired pmhc-i and endogenous il-2 and cd...
3307946 - Recurrence of acute lymphoblastic leukemia in donor cells after allogeneic marrow trans...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2013-02-25
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  10     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-04     Completed Date:  2013-09-04     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  813-30     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Molecular Imaging / methods*
Nanotechnology / methods*
Neoplastic Cells, Circulating / pathology*
Photoacoustic Techniques
Grant Support
ID/Acronym/Agency:
K22 CA131567/CA/NCI NIH HHS; K22CA131567/CA/NCI NIH HHS; R01 CA044114/CA/NCI NIH HHS; R01 CA131164/CA/NCI NIH HHS; R01 EB000873/EB/NIBIB NIH HHS; R01 EB009230/EB/NIBIB NIH HHS; R01CA131164/CA/NCI NIH HHS; R01CA44114/CA/NCI NIH HHS; R01EB000873/EB/NIBIB NIH HHS; R01EB009230/EB/NIBIB NIH HHS; R21 CA097422/CA/NCI NIH HHS; R21 CA139373/CA/NCI NIH HHS; R21 EB005123/EB/NIBIB NIH HHS; R21CA139373/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Amyloids and yeast prion biology.
Next Document:  Combined Treatment of Earlobe Keloids with Shaving, Cryosurgery, and Intralesional Steroid Injection...